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Abstract
In this paper, a mathematical modeling of Hepatitis C Virus (HCV) with Gompertzian pro-
liferation terms has been considered. The proposed mathematical model is a system of coupled
ordinary diﬀerential equations which shows the interactions between the target cells (hepato-
cytes), infected cells (infected hepatocytes), infectious virions and non-infectious virions. The
critical drug eﬃcacies of the combined drugs, interferon and ribavirin has been obtained. The
model succeeded in showing most of the dynamics in hepatitis C patients including the biphasic,
triphasic decline and the ﬂat shoulder phase.
Keywords: Gompertzian proliferation, Hepatitis C Virus (HCV), Target cells, Hepatocytes,
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1. Introduction
Worldwide, individuals between 200 to 300 millions are currently infected with Hepatitis C
virus (HCV) infection [1]. HCV infection causes a chronic disease that developed hepatic cir-
rhosis, hepatocellular carcinoma and ultimately death [2, 3, 4, 5]. In present, there are two drugs,
namely, interferon (IFN) and ribavirin, to treat a patient infected with HCV [6, 7]. Ribavirin is
eﬀective in the treatment of HCV patients with combination of interferon only.
After treating patients with combined therapy of pegylated interferon-α (PEG-IFN-α) and
ribavirin, only 50% patients show positive response [6, 8] and for non-responders, no alternative
eﬀective therapy exits [8]. Hence, there is need to identify markers of disease progression and a
reﬁnement in the therapeutic protocols, so that, there is an enhancement of long-term response
rates.
∗
Email addresses: Ram Keval@gmail.com (Ram Keval), sandofma@iitr.ernet.in (Sandip Banerjee),
sungkfma@iitr.ernet.in (S. Gakkhar)
© 2012 Published by Elsevier Ltd. Selection and/or peer-review under responsibility of Noorul Islam Centre for Higher Education.
Available online at www.sciencedirect.com
Open access under CC BY-NC-ND license.
Open access under CC BY-NC-ND license.
2454   Ram Keval et al. /  Procedia Engineering  38 ( 2012 )  2453 – 2462 
Mathematical models of HCV viral kinetics that are provided to estimate the antiviral eﬀect
of therapy, the rate of virion clearance, mechanisms of action of IFN and ribavirin [9, 10, 11,
12, 13, 14, 15]. Neumann et. al [9], used the basic model to study the viral dynamics of HCV,
which, consists of three populations and assumes a simpliﬁed view of HCV infection by taking
into account of IFN-α monotherapy. Dixit et. al. [10] made an advancement in the basic model
by taking into account the role of ribavirin action along with interferon. This model shows rib-
avirin has very little role to play during the ﬁrst phase decline induced by interferon, as ribavirin
does not alter the viral production. However, ribavirin enhances the second phase slope when
interferon eﬀectiveness is small, which is in close agreement with experiments [16] .
In the same way, Dahari [11, 12] modiﬁed Neumann’s model [9] by taking account the pro-
liferation of uninfected and infected cells driven by liver homeostatic mechanism. This model
explained biphasic, triphasic viral decline and succeeds in explaining the origins of non-response.
In a recent study, Chakrabarty and Joshi [13] presented a modiﬁed model where they used deter-
ministic control theory to obtain an optimal treatment strategy using interferon and ribavirin.
In this paper, we have considered the proliferation terms of both the target cells (hepatocytes)
and infected hepatocytes as Gompertzian growth terms. It is hypothesized that, if decay of HCV
by anti-viral therapy causes an exponential decay, we should take into account the Gompertzian
eﬀect, that is, the smaller the viral load, the steeper is the slope of lnG(t), where lnG(t) is the nat-
ural logarithm of the biological growthG(t) [17]. Therefore, it is expected that decline curve will
converge to a certain value, where decay by anti-viral therapy is equivalent to HCV replication.
In this paper, Section 2 describes the model and section 3 gives the qualitative analysis of the
model. Numerical results are discussed in section 4 and paper ends with a discussion.
2. Mathematical Model
The proposed mathematical model is a modiﬁcation of [13] and given by the following sys-
tem of coupled ordinary diﬀerential equations:
dT
dt
= s + rT ln
( Tmax
T + I
)
− d1T − (1 − cη1)αVIT (1)
dI
dt
= (1 − cη1)αVIT + rI ln
( Tmax
T + I
)
− d2I (2)
dVI
dt
=
(
1 − ηr + η1
2
)
βI − d3VI (3)
dVNI
dt
=
(
ηr + η1
2
)
βI − d3VNI (4)
In this model, target cells (T ) are produced from a source at a constant rate s. The density
dependent Gompertzian proliferation ln
(
Tmax
T+I
)
term is introduced for both target cells (hepato-
cytes) (T ) and infected hepatocytes (I). The uninfected (T ) and infected (I) hepatocytes can
proliferate proliferation rate r. Tmax is the maximum carying capacity of T and I. Here η1 de-
notes the eﬀectiveness of interferon in blocking the release of new virions, cη1 is fraction of
eﬀectiveness (0 < c < 1) and (1 − cη1) is the ineﬀectiveness of interferon. (1 − cη1)αVIT
denotes the interaction term, when target cells (T ) interact with infectious virus VI , produced
infected cells (I). In the third equation, the ﬁrst term, namely, (1 − ηr+η12 ), is ineﬀectiveness of
combined therapy by interferon and ribavirin, which leads to the growth of the infectious viri-
ons. ηr is the eﬀectiveness of ribavirin and β is infection rate constant. (
ηr+η1
2 ) is the combined
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eﬀect of ribavirin and interferon, which restricts the growth of infectious virions and results in
the growth of non-infectious virions. d1 and d2 are the natural death of target cells and infected
cells respectively. d3 is the natural death of both infectious and non-infectious virions. Here,
0 ≤ η1 < 1, 0 ≤ ηr < 1 and 0 ≤ ( ηr+η12 ) < 1 and we assume that d1 < d2 < d3 (due to clin-
ical data). More ever, System (1-4) has to be analyzed with the following initial conditions:
T (0) > 0, I(0) > 0,VI(0) > 0,VNI(0) > 0.
3. Qualitative Analysis of the model
3.1. Boundedness
Theorem 3.1.1. The solutions of system (1-4) are bounded for all t ≥ 0.
Proof 3.1.1. From (1) and (2), get
d(T + I)
dt
= s + rT ln
( Tmax
T + I
)
+ rI ln
( Tmax
T + I
)
− d1T − d2I,
< s + r(T + I) ln
( Tmax
T + I
)
− d1(T + I), as d1 < d2.
or
dW
dt
< s + rW ln
(Tmax
W
)
− d1W. (5)
where W(t) = T (t) + I(t). From (5) and (10), we have W(t) < T1 for all t ≥ 0 if T (0) < T1. Here
T (0) is the initial value of T (t) and T1 is the positive solution of equation (10). This implies that
T (t) + I(t) < T1. This shows that T(t) and I(t) is bounded. Clearly, VI is bounded from (3), say
by VI0. In the same way VNI is bounded from (4), say by VN0. So we prove that all solutions of
system (1-4) are ultimately bounded. This completes the proof.
3.2. Equilibria
For ﬁnding the equilibrium points of system (1-4), we ﬁrst put the right hand side of system
(1-4) equal to zero, which is given by
s + rT ∗ ln
( Tmax
T ∗ + I∗
)
− d1T ∗ − (1 − cη1)αV∗I T ∗ = 0 (6)
(1 − cη1)αV∗I T ∗ + rI∗ ln
( Tmax
T ∗ + I∗
)
− d2I∗ = 0 (7)(
1 − ηr + η1
2
)
βI∗ − d3V∗I = 0 (8)(
ηr + η1
2
)
βI∗ − d3V∗NI = 0 (9)
The disease free equilibrium (DFE) point is E1(T1, 0, 0, 0), where T1 is obtained from
s + rT1 ln
(
Tmax
T1
)
− d1T1 = 0. (10)
Here, T1 is the positive roots of equation (10). The endemic equilibrium point E2(T ∗, I∗,V∗I ,V
∗
NI)
is obtained as follows:
V∗I =
(
1 − ηr+η12
)
βI∗
d3
, V∗NI =
(
ηr+η1
2
)
βI∗
d3
.
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From (6) and (7), get
sI∗ + (d2 − d1)T ∗I∗ − (1 − cη1)αV∗I T ∗(T ∗ + I∗) = 0. (11)
After putting the value of V∗I in (11),we ﬁnally get I
∗ given by
I∗ = (A − T ∗) + B
T ∗
, A > T ∗.
where,
(1 − η) = (1 − cη1)
(
1 − ηr + η1
2
)
, A =
(d2 − d1)d3
(1 − η)αβ , B =
sd3
(1 − η)αβ.
After putting the values of I∗ and V∗I in (6), T
∗ can be obtained from the transcendental equation
given by
s + rT ∗ ln
(
T ∗Tmax
B + AT ∗
)
− d1T ∗ − (B + (A − T ∗)T ∗) (1 − η)αβd3 = 0. (12)
Here, T ∗ is the positive roots of equation (12).
3.3. Stability Analysis
Let E(T , I,VI ,VNI ) be any equilibrium point of a system (1-4). Then the characteristic
equation about E is given by
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
M11 − λ − rTT+I (1 − cη1)αT 0
(1 − cη1)αVI − rIT+I M22 − λ (1 − cη1)αT 0
0
(
1 − ηr+η12
)
β −d3 − λ 0
0
(
ηr+η1
2
)
β 0 −d3 − λ
∣∣∣∣∣∣∣∣∣∣∣∣∣∣
= 0. (13)
where,
M11 = −d1 − rT
T + I
− (1 − cη1)αVI + r ln
(
Tmax
T + I
)
,
M22 = −d2 − rI
T + I
+ r ln
(
Tmax
T + I
)
.
Theorem 3.3.1. The disease free equilibrium E1 is locally asymptotically stable if (1 − η) <
(d2−d1)d3+ sd3T1
αβT1
and unstable if (1 − η) > (d2−d1)d3+
sd3
T1
αβT1
, where η is the overall drug eﬃency.
Proof 3.3.1. By using (10), characteristic equation (13) about DFE point E1(T1, 0, 0, 0), reduces
to
(λ + d3)
(
λ + r +
s
T1
)
(λ2 +C1λ +C2) = 0. (14)
where,
C1 = (d2 − d1) + d3 > 0 as d1 < d2, C2 = (d2 − d1)d3 + sd3T1 − (1 − η)αβT1.
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As we know that for local stability of any equilibrium point, characteristic equation about that
point have negative roots or roots with negative real parts. In this case, characteristic equation
(14) have two roots λ = −d3,−
(
r + sT1
)
, which is negative and two roots is given by λ2 + C1λ +
C2 = 0. By Routh-Hurwize criterion, two roots will have negative real parts if C1 > 0 and C2 > 0.
Clearly given that C1 > 0 and C2 > 0 if
(1 − η) = (1 − cη1)
(
1 − ηr + η1
2
)
<
(d2 − d1)d3 + sd3T1
αβT1
.
This completes the proof.
Theorem 3.3.2. The infected equilibrium point E2 is locally asymptotically stable if, A4 =(
r + d3 + sT ∗ +
(1−η)αβT ∗
d3
) (
rd3 +
sd3
T ∗ +
rsI∗
T ∗(T ∗+I∗) +
(1−η)αβ(s+rT ∗)
d3
)
−
(
rsd3I∗
T ∗(T ∗+I∗) +
(1−η)2α2β2T ∗I∗
d3
)
> 0.
Proof 3.3.2. As E2(T ∗, I∗,V∗I ,V
∗
NI) is the equilibrium point of the system (1-4), then from equa-
tion (6)
r ln
( Tmax
T ∗ + I∗
)
− d1 − (1 − cη1)αV∗I = −
s
T ∗
, (15)
From (7)
r ln
( Tmax
T ∗ + I∗
)
− d2 = −
(1 − cη1)αV∗I T ∗
I∗
, (16)
and from (8)
V∗I =
(
1 − ηr+η12
)
βI∗
d3
. (17)
After using (15), (16) and then (17) in (13), characteristic equation (13) about infected equilib-
rium point E2 can be written as
(λ + d3)(λ3 + A1λ2 + A2λ + A3) = 0. (18)
where,
A1 = r + d3 +
s
T ∗
+
(1 − η)αβT ∗
d3
> 0,
A2 = rd3 +
sd3
T ∗
+
rsI∗
T ∗(T ∗ + I∗)
+
(1 − η)αβ(s + rT ∗)
d3
> 0,
A3 =
rsd3I∗
T ∗(T ∗ + I∗)
+
(1 − η)2α2β2T ∗I∗
d3
> 0,
A4 = A1A2 − A3 =
(
r + d3 +
s
T ∗
+
(1 − η)αβT ∗
d3
) (
rd3 +
sd3
T ∗
+
rsI∗
T ∗(T ∗ + I∗)
+
(1 − η)αβ(s + rT ∗)
d3
)
−
(
rsd3I∗
T ∗(T ∗ + I∗)
+
(1 − η)2α2β2T ∗I∗
d3
)
.
Clearly, one root of characteristic equation (18) is negative and by the Routh-Hurwitz criterion,
the other roots will be negative if A1, A2, A3 > 0 and A4 = A1A2 − A3 > 0. Here, we can see
that A1, A2 and A3 is greater than zero. So, the infected equilibrium point E2(T ∗, I∗,V∗I ,V
∗
NI) is
locally asymptotically stable, provided that A4 =
(
r + d3 + sT ∗ +
(1−η)αβT ∗
d3
) (
rd3 +
sd3
T ∗ +
rsI∗
T ∗(T ∗+I∗) +
(1−η)αβ(s+rT ∗)
d3
)
−
(
rsd3I∗
T ∗(T ∗+I∗) +
(1−η)2α2β2T ∗I∗
d3
)
> 0. This completes the proof.
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3.4. Critical drug eﬃcacy
In system (1-4), the eﬀectiveness of interferon and ribavirin are given by the terms (1 − cη1)
and
(
1 − ηr+η12
)
. Here, these terms are combined into a single term as (1−cη1)
(
1 − ηr+η12
)
= (1−η),
where η represents the overall drug eﬃciency. Clearly, η1 = ηr = 0, that is, drug eﬃciency is
zero before treatment and 0 < η1 ≤ 1, 0 < ηr ≤ 1 during antiviral therapy. The local stability
criteria for disease free equilibrium E1 is
(1 − η) < (d2 − d1)d3 +
sd3
T1
αβT1
This clearly indicates that there exists a point that acts as a point of separation between the region
of stability for disease free equilibrium and the region of stability for infected steady state. This
point can be termed as a transcritical bifurcation point, which is given by
(1 − η) = (d2 − d1)d3 +
sd3
T1
αβT1
So, the critical drug eﬃcacy is deﬁned as
ηc = 1 −
(d2 − d1)d3 + sd3T1
αβT1
.
During antiviral therapy, if η > ηc, the drug therapy is successful and the viral load can be
eradicated. On the other hand, if η < ηc, the viral load and the infected cells converge to a new
steady state with lower values.
4. Numerical Simulation
We now performed numerical simulation on the system (1-4). All parameter values are ob-
tained from [10, 11] as follows: s = 1.0 cell ml−1 day−1, r = 2.0 day−1, Tmax = 3.6 × 107 cells
ml−1, d1 = 0.01 day−1, d2 = 1.0 day−1, d3 = 6.0 day−1, α = 2.25 × 10−7 ml day−1 virions−1 and
β = 2.9 virions cell−1day−1.We have considered initial HCV RNA (Viral load) of 107 copies ml−1
in all ﬁgures generated through numerical simulations. Numerical value of critical drug eﬃcacy
ηc is 0.75.
Thus, ﬁg.1(a) shows the kinetics of the HCV RNA decline in patients responding to inter-
feron monotherapy (ηr = 0), which is biphasic in nature. This behavior has also been observed
clinically [9? ? ]. Fig.1(b) shows the same kinetics of the HCV RNA decline in addition of
ribavirin (ηr = 0.3) along with interferon. This conforms the fact that ribavirin fails to change
the dynamics of HCV RNA when the eﬀectiveness of interferon is eﬀectively large ( that is rib-
avirin does not have signiﬁcant impact on the second phase decline of HCV RNA, when the
eﬀectiveness of interferon is large).
Fig.2(a) shows the dynamics of HCVRNAwith lower interferon eﬃcacy and varying eﬃcacy
of ribavirin. This shows when interferon eﬃcacy is small, ribavirin renders progeny virions non-
infectious and enhances the second phase decline. Fig.2(b) shows the ribavirin monotherapy of
HCV RNA. This implies that ribavirin alone has no eﬀect on decline of HCV RNA.
Fig.3 shows the viral kinetics after the therapy cessation. A virus resurgence post therapy
cessation with diﬀerent drug eﬃcacies (η = 0.73, 0.85, 0.96) from time 0 to 14 days and then set
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η to zero for the rest of the simulation. After 14 days, the virus resurges to pretreatment levels
within (7-7.5) days of post therapy cessation. Thus, the model given by system (1-4), predicts
resurgences to pretreatment levels after cessation of therapy.
Fig.4 (a) shows the HCV RNA dynamics when inﬂux rate of new hepatocytes is very low,
which is triphasic in nature. The ﬁrst phase shows a rapid viral decline, followed by a ﬂat or
shoulder phase, in which the viral load remains constant and a third phase of faster viral decay.
Here, the ﬂat phase, where the constant infected cell level is maintained, is the focus of our
discussion. Fig.4 (b) shows the HCV RNA dynamics with higher inﬂux rate of new hepatocytes,
s, shrinks the shoulder phase and even eliminates it giving rise to a biphasic viral decline.
5. Conclusion
Hepatitis C virus is aﬀecting millions of people with high levels of morbidity and mortality
[6]. The combined therapy of interferon-α and ribavirin has been able to eradicate the virus in a
substantial number of patients. In this model, density dependent Gompertzian proliferation terms
of both uninfected and infected hepatocytes have been used. The model succeeded in explaining
the virus resurges to pretreatment levels within a week of post therapy cessation, the biphasic
decline of viral load, the triphasic decline in viral decay, including the ﬂat or shoulder phase.
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The ﬁg.1(a) shows the interferon monotherapy. Fig.1(b) shows that ribavirin fails to change the
dynamics of HCV RNA when the eﬀectiveness of interferon is eﬀectively large.
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Fig.2(a) shows the dynamics of HCV RNA with lower interferon eﬃcacy and eﬃcacy of rib-
avirin. Fig.2(b) shows the ribavirin monotherapy.
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Fig.3 shows the HCV RNA kinetics after the therapy cessation. Here, the following parameter
values have been used. s = 2.6× 104 cell ml−1 day−1, r = 4.2 day−1, Tmax = 1.0× 107 cells ml−1,
d1 = 0.0026 day−1, d2 = 0.26 day−1
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Fig.4(a) shows the triphasic dynamics of HCV RNA. Fig.4(b) shows that higher inﬂux rates of
new hepatocytes, s, shrinks the shoulder phase and even eliminates it giving rise to a biphasic
viral decline.
